Boehringer Ingelheim’s Survodutide Shows Breakthrough Improvement in Liver Fibrosis with No Worsening of MASH in 64.5% of Patients with F2 and F3 Fibrosis
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%). New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH.1 Additional sub-analysis shows [...]